{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:11:16Z","timestamp":1790683876437,"version":"4.1.0"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Post-transplant thrombotic microangiopathy (PT-TMA) is an uncommon but severe complication of kidney transplantation associated with graft dysfunction and poor outcomes. Although infections have been recognized as potential triggers, systemic thrombotic microangiopathy associated with cytomegalovirus (CMV) infection remains rarely reported. Experimental and clinical evidence suggests that CMV may promote endothelial injury and complement activation, mechanisms that could contribute to the development of microangiopathic processes in transplant recipients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      We report the case of a 78-year-old kidney transplant recipient who developed\n                      <jats:italic>de novo<\/jats:italic>\n                      systemic thrombotic microangiopathy associated with CMV infection. The patient presented with thrombocytopenia, microangiopathic hemolytic anemia, and progressive graft dysfunction. Drug-induced TMA related to recent tacrolimus initiation was initially suspected; however, hematologic abnormalities persisted despite calcineurin inhibitor withdrawal. Further evaluation revealed significant CMV viremia (54,000 copies\/mL), while additional viral, gastrointestinal infectious, and autoimmune evaluations did not identify a more likely alternative explanation. Intravenous ganciclovir therapy was initiated and later transitioned to oral valganciclovir. Following comprehensive management, including withdrawal of tacrolimus and targeted antiviral therapy, hemolysis resolved, platelet counts normalized, CMV viral load progressively declined until clearance, and renal graft function improved. Immunosuppression was subsequently reintroduced using a calcineurin inhibitor\u2013free regimen with belatacept.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      CMV infection should be considered a plausible trigger of\n                      <jats:italic>de novo<\/jats:italic>\n                      post-transplant thrombotic microangiopathy, particularly in patients with persistent disease despite withdrawal of calcineurin inhibitors. Although post-transplant TMA is frequently multifactorial, early recognition of CMV viremia and timely comprehensive management addressing all contributing factors may be associated with favorable hematologic recovery and improvement of graft function.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1910374","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:10:18Z","timestamp":1785237018000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Cytomegalovirus viremia associated with systemic thrombotic microangiopathy after kidney transplantation: a case report"],"prefix":"10.3389","volume":"13","author":[{"given":"Andres David","family":"Sastre-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Internal Medicine Department, Universidad del Valle","place":["Cali, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. A.","family":"Nati-Castillo","sequence":"additional","affiliation":[{"name":"Grupo de Investigaci\u00f3n en Biomateriales y Biotecnolog\u00eda - BEO, Facultad de Salud, Universidad Santiago de Cali","place":["Cali, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Fernando","family":"Acu\u00f1a-Roldan","sequence":"additional","affiliation":[{"name":"Organ and Tissue Transplant Unit, Cl\u00ednica Imbanaco","place":["Cali, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlon","family":"Arias-Intriago","sequence":"additional","affiliation":[{"name":"One Health Research Group, Universidad de las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronnie","family":"Calupi\u00f1a-Larco","sequence":"additional","affiliation":[{"name":"Departamento de Urolog\u00eda, Hospital Interzonal General de Agudos Evita Pueblo de Berazategui","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego A.","family":"Lucero-Guanga","sequence":"additional","affiliation":[{"name":"Health Faculty, Universidad Libre, Seccional Cali","place":["Cali, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhan S.","family":"Saavedra-Torres","sequence":"additional","affiliation":[{"name":"Fundaci\u00f3n Universitaria Visi\u00f3n de las Am\u00e9ricas, Grupo de investigaci\u00f3n Biomedicina","place":["Pereira, Colombia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan S.","family":"Izquierdo-Condoy","sequence":"additional","affiliation":[{"name":"One Health Research Group, Universidad de las Am\u00e9ricas","place":["Quito, Ecuador"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1002\/art.42681","article-title":"Clinical evaluation and management of thrombotic Microangiopathy","volume":"76","author":"Leisring","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1146\/annurev.pathmechdis.3.121806.154311","article-title":"Pathogenesis of thrombotic Microangiopathies","volume":"3","author":"Zheng","year":"2008","journal-title":"Annu Rev Pathol Mech Dis"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1056\/NEJMra1312353","article-title":"Syndromes of thrombotic microangiopathy","volume":"371","author":"George","year":"2014","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.2215\/CJN.11470918","article-title":"Etiology and outcomes of thrombotic microangiopathies","volume":"14","author":"Bayer","year":"2019","journal-title":"Clin J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"122","DOI":"10.5500\/wjt.v8.i5.122","article-title":"Thrombotic microangiopathy after renal transplantation: current insights in de novo and recurrent disease","volume":"8","author":"Abbas","year":"2018","journal-title":"World J Transplant"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1432-2277.2006.00354.x","article-title":"Thrombotic microangiopathy after kidney transplantation","volume":"19","author":"Ponticelli","year":"2006","journal-title":"Transpl Int"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/ckj\/sfz040","article-title":"An updated classification of thrombotic microangiopathies and treatment of complement gene variant-mediated thrombotic microangiopathy","volume":"12","author":"Aigner","year":"2019","journal-title":"Clin Kidney J"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"642864","DOI":"10.3389\/fmed.2021.642864","article-title":"Thrombotic Microangiopathy after kidney transplantation: an underdiagnosed and potentially reversible entity","volume":"8","author":"\u00c1vila","year":"2021","journal-title":"Front Med"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12882-023-03326-8","article-title":"Thrombotic microangiopathies after kidney transplantation in modern era: nosology based on chronology","volume":"24","author":"Von Tokarski","year":"2023","journal-title":"BMC Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1093\/cid\/ciae321","article-title":"Consensus definitions of cytomegalovirus (CMV) infection and disease in transplant patients including resistant and refractory CMV for use in clinical trials: 2024 update from the transplant associated virus infections forum","volume":"79","author":"Ljungman","year":"2024","journal-title":"Clin Infect Dis"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1111\/tri.12582","article-title":"Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature","volume":"28","author":"Java","year":"2015","journal-title":"Transpl Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.transproceed.2011.11.052","article-title":"Spectrum of cytomegalovirus-induced renal pathology in renal allograft recipients","volume":"44","author":"Rane","year":"2012","journal-title":"Transplant Proc"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3390\/v16071171","article-title":"The interactions of the complement system with human cytomegalovirus","volume":"16","author":"Lujan","year":"2024","journal-title":"Viruses"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1128\/CVI.00011-12","article-title":"Cytomegalovirus-induced effector T cells cause endothelial cell damage","volume":"19","author":"Van De Berg","year":"2012","journal-title":"Clin Vaccine Immunol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e12708","DOI":"10.1002\/rth2.12708","article-title":"Thrombotic microangiopathies: an illustrated review","volume":"6","author":"Abou-Ismail","year":"2022","journal-title":"Res Pract Thromb Haemost"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1182\/asheducation-2017.1.651","article-title":"Thrombocytopenia in hospitalized patients: approach to the patient with thrombotic microangiopathy","volume":"2017","author":"Scully","year":"2017","journal-title":"Hematology"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"11","DOI":"10.4285\/kjt.23.0011","article-title":"Characteristics and management of thrombotic microangiopathy in kidney transplantation","volume":"37","author":"Cho","year":"2023","journal-title":"Korean J Transplant"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0227445","DOI":"10.1371\/journal.pone.0227445","article-title":"Clinical and pathological features of thrombotic microangiopathy influencing long-term kidney transplant outcomes","volume":"15","author":"Teixeira","year":"2020","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"160","DOI":"10.4103\/1319-2442.279936","article-title":"Clinical profile and outcomes of de novo posttransplant thrombotic microangiopathy","volume":"31","author":"Saikumar Doradla","year":"2020","journal-title":"Saudi J Kidney Dis Transpl"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1016\/j.ajt.2024.01.029","article-title":"De novo thrombotic microangiopathy after kidney transplantation in adults: interplay between complement genetics and multiple endothelial injury","volume":"24","author":"Dessaix","year":"2024","journal-title":"Am J Transplant"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1016\/j.ekir.2025.01.026","article-title":"Thrombotic Microangiopathy after kidney transplantation: insights into genetic etiology and clinical outcomes","volume":"10","author":"Merzkani","year":"2025","journal-title":"Kidney Int Rep"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"e2496","DOI":"10.1002\/rmv.2496","article-title":"Relationship of human cytomegalovirus-infected endothelial cells and circulating leukocytes in the pathogenesis of disseminated human cytomegalovirus infection: a narrative review","volume":"34","author":"Gerna","year":"2024","journal-title":"Rev Med Virol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1002\/rmv.645","article-title":"Human cytomegalovirus tropism for endothelial\/epithelial cells: scientific background and clinical implications","volume":"20","author":"Revello","year":"2010","journal-title":"Rev Med Virol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.3390\/ijms25020812","article-title":"Investigation of clinical features and association between vascular endothelial injury markers and cytomegalovirus infection associated with thrombotic Microangiopathy in patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated Vasculitis: case-based research","volume":"25","author":"Nimura","year":"2024","journal-title":"Int J Mol Sci"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1128\/JVI.79.4.2211-2220.2005","article-title":"Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation","volume":"79","author":"Rahbar","year":"2005","journal-title":"J Virol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1186\/s12936-026-05838-8","article-title":"Ischemic stroke during dengue\u2013plasmodium vivax coinfection in a young woman: a case report","volume":"25","author":"Nati-Castillo","year":"2026","journal-title":"Malar J"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.freeradbiomed.2023.12.002","article-title":"UCHL1 deficiency upon HCMV infection induces vascular endothelial inflammatory injury mediated by mitochondrial iron overload","volume":"211","author":"Zhu","year":"2024","journal-title":"Free Radic Biol Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/S0272-6386(99)70085-5","article-title":"De novo hemolytic uremic syndrome postrenal transplant after cytomegalovirus infection","volume":"34","author":"Waiser","year":"1999","journal-title":"Am J Kidney Dis"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1097\/00007890-199806270-00018","article-title":"Thrombotic microangiopathy in association with cytomegalovirus infection in a renal transplant patient: a new treatment strategy","volume":"65","author":"Jeejeebhoy","year":"1998","journal-title":"Transplantation"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1159\/000321328","article-title":"De novo thrombotic Microangiopathy induced by cytomegalovirus infection leading to renal allograft loss","volume":"32","author":"De Keyzer","year":"2010","journal-title":"Am J Nephrol"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1111\/ajt.13023","article-title":"Adoptive T cell immunotherapy for treatment of ganciclovir-resistant cytomegalovirus disease in a renal transplant recipient","volume":"15","author":"Macesic","year":"2015","journal-title":"Am J Transplant"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21926\/obm.transplant.2303194","article-title":"A rare and complex case of multifactorial thrombotic microangiopathy in a kidney transplant recipient: interplay between antibody mediated rejection, tacrolimus toxicity, cytomegalovirus disease and BNT162b2mRNA vaccine","volume":"7","author":"Naidu","year":"2023","journal-title":"OBM Transplant"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.modpat.2024.100690","article-title":"Etiology and outcomes of kidney-limited and systemic thrombotic Microangiopathy","volume":"38","author":"Van Doorn","year":"2025","journal-title":"Mod Pathol"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","article-title":"The fourth international consensus guidelines on the Management of Cytomegalovirus in solid organ transplantation","volume":"109","author":"Kotton","year":"2025","journal-title":"Transplantation"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"sfag018","DOI":"10.1093\/ckj\/sfag018","article-title":"Thrombotic microangiopathy after kidney transplantation: diagnosis and management strategies","volume":"19","author":"Mirioglu","year":"2026","journal-title":"Clin Kidney J"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.cmi.2023.03.020","article-title":"Oral antiviral drugs for treatment of cytomegalovirus in transplant recipients","volume":"29","author":"Razonable","year":"2023","journal-title":"Clin Microbiol Infect"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"11785","DOI":"10.3389\/ti.2023.11785","article-title":"New treatment options for refractory\/resistant CMV infection","volume":"36","author":"Walti","year":"2023","journal-title":"Transpl Int"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.ekir.2024.01.013","article-title":"\u201cEculizumab first\u201d in the management of posttransplant thrombotic microangiopathy","volume":"9","author":"Maritati","year":"2024","journal-title":"Kidney Int Rep"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1910374\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T11:10:18Z","timestamp":1785237018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1910374\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":38,"alternative-id":["10.3389\/fmed.2026.1910374"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1910374","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"article-number":"1910374"}}